Summit Therapeutics (SMMT)

Cash used, 12 months
$527M12 months to Sep 30, 2026 (10-Q)
Net cash
$630Mat Sep 30, 2026
Worst fall since listing
−95.8%Sep 11, 2017 to Dec 1, 2022; back to that high in Sep 2024

THE FULL STORY Summit Therapeutics: One Man, One Drug and a $500 Million Check

About the company

The Long View

What the filings say about the story, dilution and cash runway.

No Long View yet. Request one →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

Long-term fundamentals

Annual results for Summit Therapeutics, FY2020–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Revenue went from $0.9M in FY2020 to $0.7M in FY2022. Free cash flow was positive in 0 of the 6 years shown; FY2025: −$324M. Each year's figures are in the table below. −$400M−$300M−$200M−$100M$0$100M ’20 ’21 ’22 ’23 ’24 ’25

Revenue went from $0.9M in FY2020 to $0.7M in FY2022.

Free cash flow was positive in 0 of the 6 years shown; FY2025: −$324M.

Margins

Margins are not charted: in FY2022 the operating loss (−$72M) was larger than revenue ($0.7M). The table has each year's figures.

Diluted share count

The diluted share count rose 653% from FY2020 to FY2025, to 748M. Each year's figures are in the table below. 0M200M400M600M800M ’20’21’22’23’24’25

The diluted share count rose 653% from FY2020 to FY2025, to 748M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025———−$1.1B−$323M$0.7M−$324M
FY2024$0——−$221M−$142M$0.1M−$142M
FY2023$0——−$615M−$77M$0.1M−$77M
FY2022$0.7M—−10225%−$79M−$42M$0.6M−$42M
FY2021$2M—−4764%−$89M−$73M$0.3M−$73M
FY2020$0.9M—−6185%−$53M−$48M$0.4M−$49M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY2025748M$713M—$732M——
FY2024719M$412M—$51M——
FY2023620M$186M$100M$14M——
FY2022193M$349M$514M$12M——
FY2021132M$72M—$13M——
FY202099M$66M—$2M$0—

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 18, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

  • Years before the company changed its fiscal year-end are left out (the last one ended 2019-01-31), so every year shown covers the same 12 months.
  • Diluted shares are restated to the current share basis (stock splits or reverse splits), chaining year-over-year changes reported in each 10-K.

Returns by year

YearSMMTS&P 500
2019+39.1%+31.5%
2020+193.8%+18.4%
2021−42.8%+28.7%
2022+58.0%−18.1%
2023−38.6%+26.3%
2024+583.7%+25.0%
2025−2.0%+17.9%
2026 to date−39.6%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.